Julien strongly believes that medicine and healthcare are on the cusp of a major transformation driven by new technologies representing an unprecedented opportunity for patient outcome in Asia. As the Co-Founder and Managing Director of Galen Growth Asia, he acts as The Asia HealthTech Connector and ecosystem catalyst and his mission it is to foster a sustainable and vibrant HealthTech ecosystem across Asia.
With over 15 years of experience in healthcare with leading brands including Eli Lilly, Boston Scientific, Baxter, GSK, Merck &Co., he has a deep understanding of organic and inorganic growth in healthcare in both developed and emerging markets. He has gained extensive international business experience across Europe, Middle East and Asia.
In 2012, Julien founded The Propell Group, a boutique venture investor and advisory firm, based in Singapore, which focuses on HealthTech startups and growth companies. He has also co-founded the Global Cancer Research & Commercialisation Fund in 2016 to establish greater collaboration and open innovation between research institutes, research foundations and investors from all corners of the globe. The fund’s goal is to harness technology and business model innovation to deliver superior financial returns and, most importantly, drive better outcomes for cancer patients.